Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Shares of the innovative clinical-stage biotechnology company bluebird bio Inc. (NASDAQ: BLUE) have jumped more than 13% Tuesday, after the company together with their partner Celgene Corporation (NASDAQ: CELG) reported updated results from the ongo..